Display options
Cite
Turner AR, Lane BR, Rogers D, et al. Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men. Cancer. 2016;122(22):3564-3575doi: 10.1002/cncr.30162.
Turner, A. R., Lane, B. R., Rogers, D., Lipkus, I., Weaver, K., Danhauer, S. C., Zhang, Z., Hsu, F. C., Noyes, S. L., Adams, T., Toriello, H., Monroe, T., McKanna, T., Young, T., Rodarmer, R., Kahnoski, R. J., Tourojman, M., Kader, A. K., Zheng, S. L., Baer, W., & Xu, J. (2016). Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men. Cancer, 122(22), 3564-3575. https://doi.org/10.1002/cncr.30162
Turner, Aubrey R, et al. "Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men." Cancer vol. 122,22 (2016): 3564-3575. doi: https://doi.org/10.1002/cncr.30162
Turner AR, Lane BR, Rogers D, Lipkus I, Weaver K, Danhauer SC, Zhang Z, Hsu FC, Noyes SL, Adams T, Toriello H, Monroe T, McKanna T, Young T, Rodarmer R, Kahnoski RJ, Tourojman M, Kader AK, Zheng SL, Baer W, Xu J. Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men. Cancer. 2016 Nov 15;122(22):3564-3575. doi: 10.1002/cncr.30162. Epub 2016 Jul 19. PMID: 27433786; PMCID: PMC5247411.
Copy Download .nbib Format: NLM
Share it on

Cancer. 2016 Nov 15;122(22):3564-3575. doi: 10.1002/cncr.30162. Epub 2016 Jul 19.

Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men.

Cancer

Aubrey R Turner, Brian R Lane, Dan Rogers, Isaac Lipkus, Kathryn Weaver, Suzanne C Danhauer, Zheng Zhang, Fang-Chi Hsu, Sabrina L Noyes, Tamara Adams, Helga Toriello, Thomas Monroe, Trudy McKanna, Tracey Young, Ryan Rodarmer, Richard J Kahnoski, Mouafak Tourojman, A Karim Kader, S Lilly Zheng, William Baer, Jianfeng Xu

Affiliations

  1. Center for Cancer Genomics, Wake Forest School of Medicine, Winston-Salem, North Carolina.
  2. Spectrum Health Hospital System, Grand Rapids, Michigan.
  3. College of Human Medicine, Michigan State University, Grand Rapids, Michigan.
  4. Van Andel Research Institute, Grand Rapids, Michigan.
  5. School of Nursing, Duke University, Durham, North Carolina.
  6. Department of Social Sciences and Health Policy, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina.
  7. Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina.
  8. Department of Surgery, University of California San Diego, San Diego, California.
  9. Grand Valley Medical Specialists, Grand Rapids, Michigan.

PMID: 27433786 PMCID: PMC5247411 DOI: 10.1002/cncr.30162

Abstract

BACKGROUND: Prostate-specific antigen (PSA) screening may reduce death due to prostate cancer but leads to the overdiagnosis of many cases of indolent cancer. Targeted use of PSA screening may reduce overdiagnosis. Multimarker genomic testing shows promise for risk assessment and could be used to target PSA screening.

METHODS: To test whether counseling based on the family history (FH) and counseling based on a genetic risk score (GRS) plus FH would differentially affect subsequent PSA screening at 3 months (primary outcome), a randomized trial of FH versus GRS plus FH was conducted with 700 whites aged 40 to 49 years without prior PSA screening. Secondary outcomes included anxiety, recall, physician discussion at 3 months, and PSA screening at 3 years. Pictographs versus numeric presentations of genetic risk were also evaluated.

RESULTS: At 3 months, no significant differences were observed in the rates of PSA screening between the FH arm (2.1%) and the GRS-FH arm (4.5% with GRS-FH vs. 2.1% with FH: χ

CONCLUSIONS: This is likely the first randomized trial of multimarker genomic testing to report genomic targeting of cancer screening. This study found little evidence of concern about excess anxiety or overuse/underuse of PSA screening when multimarker genetic risks were provided to patients. Cancer 2016;122:3564-3575. © 2016 American Cancer Society.

© 2016 American Cancer Society.

Keywords: genetic counseling; genetic risk score; genetic testing; prostate cancer; prostate-specific antigen (PSA) screening; randomized controlled trial

References

  1. J Intern Med. 2012 Apr;271(4):344-52 - PubMed
  2. Prostate. 2009 Oct 1;69(14):1565-72 - PubMed
  3. J Natl Cancer Inst. 2003 Dec 3;95(23):1792-7 - PubMed
  4. BJU Int. 2012 Oct;110 Suppl 1:3-7 - PubMed
  5. N Engl J Med. 2010 Mar 18;362(11):986-93 - PubMed
  6. Prostate. 1990;17(4):337-47 - PubMed
  7. J Clin Oncol. 2012 Jul 20;30(21):2581-4 - PubMed
  8. BMC Med Inform Decis Mak. 2013 Apr 29;13:55 - PubMed
  9. Patient Educ Couns. 2008 Dec;73(3):448-55 - PubMed
  10. N Engl J Med. 2009 Jul 16;361(3):245-54 - PubMed
  11. J Natl Cancer Inst. 2011 May 18;103(10):788-97 - PubMed
  12. Med Care. 2003 May;41(5):582-92 - PubMed
  13. Prostate. 2009 Mar 1;69(4):363-72 - PubMed
  14. J Genet Couns. 2012 Aug;21(4):547-56 - PubMed
  15. Genet Med. 2015 Oct;17(10):789-95 - PubMed
  16. Eur Urol. 2010 Aug;58(2):275-80 - PubMed
  17. Prostate. 2010 Dec 1;70(16):1729-38 - PubMed
  18. Genet Med. 2007 May;9(5):290-7 - PubMed
  19. Ann Intern Med. 2014 Oct 21;161(8):537-45 - PubMed
  20. Nicotine Tob Res. 2015 Mar;17(3):337-43 - PubMed
  21. N Engl J Med. 2008 Feb 28;358(9):910-9 - PubMed
  22. Genet Epidemiol. 2011 Sep;35(6):549-56 - PubMed
  23. N Engl J Med. 2010 Mar 18;362(11):1043-5 - PubMed
  24. Br J Cancer. 2015 Sep 29;113(7):1086-93 - PubMed
  25. Prev Med. 2000 Jul;31(1):75-80 - PubMed
  26. PLoS One. 2011;6(10):e27130 - PubMed
  27. N Engl J Med. 2011 Feb 10;364(6):524-34 - PubMed
  28. Eur Urol. 2011 Jul;60(1):21-8 - PubMed
  29. Am J Med Genet A. 2003 Apr 30;118A(3):201-9 - PubMed
  30. Ann Intern Med. 2012 Jul 17;157(2):120-34 - PubMed
  31. Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):437-44 - PubMed
  32. Nat Rev Urol. 2014 Jan;11(1):18-31 - PubMed
  33. JAMA. 2004 Sep 22;292(12):1480-9 - PubMed

Publication Types

Grant support